Opportunity BasketReimbursement Evidence Cooperative (REC)
A shared-cost clinical evidence consortium where 5–12 women's health startups pool capital, patient data, and regulatory burden to fund and execute 2–3 joint real-world evidence (RWE) studies that benefit all members. A dedicated reimbursement strategist and regulatory affairs manager coordinate study design, payer engagement, and evidence packaging—reducing per-company cost from $500K–$2M to $80K–$200K per company.
92 weeks • 70% confidence
Value Proposition
Startups get clinical evidence and payer-ready documentation at 1/5 the cost and 2/3 the timeline of solo studies, plus direct access to a reimbursement strategist who knows payer playbooks. The cooperative structure removes the revenue-to-evidence catch-22 by distributing fixed costs across multiple revenue streams.
Target Audience
Series A/B women's health startups (contraception, menopause, reproductive mental health, gynecologic care) with complementary products (not direct competitors) and $2M+ ARR seeking insurance coverage in the US market.
Key Features
- Cohort-based RWE study design (e.g., real-world outcomes in menopause treatment, contraceptive satisfaction, mental health outcomes) that serves 3–5 products simultaneously
- Shared patient registry and data infrastructure (HIPAA-compliant, IRB-approved) that member companies feed into and query
- Dedicated reimbursement strategist who maps each payer's evidence thresholds, negotiates study scope, and packages results into coverage submissions
- And more, with full implementation detail...
Tech Stack
Unlock the full solution
You're seeing a preview. Unlock the complete value proposition, every feature, the full tech stack, the monetization model, and the week-by-week build roadmap, plus a downloadable PDF.
Sign up free to continue3 free solution credits on signup
The build plan is behind the wall
Subscribers get the full monetization model, pricing strategy, and the complete week-by-week roadmap to build this.
Sign up freeOriginal Problem
Women's health startups cannot secure insurance reimbursement due to insufficient clinical evidenceWomen's health companies struggle to get their products and services covered by insurance because they lack the clinical research and real-world evidence that payers demand. This creates a catch-22: startups need revenue to fund studies, but can't generate revenue without reimbursement coverage. Current solutions fail because the evidence requirements are expensive, time-consuming, and startups lack guidance on reimbursement strategy from inception.
Score: 46.2% • 1 demand signal